BioCardia (BCDA) 10-Q19 Nov 192019 Q3 Quarterly reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2019	Nov. 12, 2019
Document Information [Line Items]
Entity Registrant Name	BioCardia, Inc.
Entity Central Index Key	0000925741
Trading Symbol	bcda
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		6,825,183
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock, par value $0.001

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 8,910,000	$ 5,358,000
Accounts receivable, net of allowance for doubtful accounts of $14 and $9 at September 30, 2019 and December 31, 2018	103,000	274,000
Inventory	45,000	141,000
Prepaid expenses and other current assets	179,000	445,000
Total current assets	9,237,000	6,218,000
Property and equipment, net	210,000	145,000
Operating lease right-of-use asset, net	1,180,000
Other assets	54,000	54,000
Total assets	10,681,000	6,417,000
Current liabilities:
Accounts payable	1,112,000	743,000
Accrued expenses and other current liabilities	2,424,000	1,805,000
Operating lease liability - current	508,000
Total current liabilities	4,044,000	2,548,000
Operating lease liability - noncurrent	752,000
Deferred revenue - noncurrent	691,000
Deferred rent		77,000
Total liabilities	5,487,000	2,625,000
Stockholders’ equity:
Preferred stock, $0.001 par value, 25,000,000 shares authorized as of September 30, 2019 and December 31, 2018; no shares issued and outstanding as of September 30, 2019 and December 31, 2018
Common stock, $0.001 par value, 100,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 6,825,183 and 4,845,697 shares issued and outstanding as of September 30, 2019 and December 31, 2018	46,000	43,000
Additional paid-in capital	102,716,000	90,110,000
Accumulated deficit	(97,568,000)	(86,361,000)
Total stockholders’ equity	5,194,000	3,792,000
Total liabilities and stockholders’ equity	$ 10,681,000	$ 6,417,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Allowance for doubtful accounts	$ 14	$ 9
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	25,000,000	25,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	6,825,183	4,845,697
Common stock, shares outstanding (in shares)	6,825,183	4,845,697

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue:
Total revenue	$ 194	$ 84	$ 495	$ 522
Costs and expenses:
Cost of goods sold	24	109	321	401
Research and development	2,007	2,262	6,392	6,248
Selling, general and administrative	1,390	1,283	4,460	4,315
Total costs and expenses	3,421	3,654	11,173	10,964
Operating loss	(3,227)	(3,570)	(10,678)	(10,442)
Other income (expense):
Interest income	17	29	53	100
Gain on change in fair value of redemption feature embedded in convertible notes	52		52
Interest expense	(112)		(112)
Loss on extinguishment of convertible notes	(521)		(521)
Other expense	(1)	(3)	(2)	(3)
Total other income (expense)	(565)	26	(530)	97
Net loss	$ (3,792)	$ (3,544)	$ (11,208)	$ (10,345)
Net loss per share, basic and diluted (in dollars per share)	$ (0.63)	$ (0.83)	$ (2.13)	$ (2.43)
Weighted-average shares used in computing net loss per share, basic and diluted (in shares)	6,030,662	4,253,100	5,263,058	4,250,509
Product [Member]
Revenue:
Total revenue	$ 1	$ 52	$ 139	$ 223
Collaboration Agreement [Member]
Revenue:
Total revenue	$ 193	$ 32	$ 356	$ 299

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017	4,246,519
Balance at Dec. 31, 2017	$ 38	$ 83,537	$ (72,450)	$ 11,125
Restricted stock units vested and issued (in shares)	2,271
Restricted stock units vested and issued
Share-based compensation		615		615
Net loss			(3,584)	(3,584)
Adjustments to opening balance for change in accounting principle			46	46
Exercise of stock options (in shares)	237
Exercise of stock options		5		5
Balance (in shares) at Mar. 31, 2018	4,249,027
Balance at Mar. 31, 2018	$ 38	84,157	(75,988)	8,207
Balance (in shares) at Dec. 31, 2017	4,246,519
Balance at Dec. 31, 2017	$ 38	83,537	(72,450)	11,125
Net loss				(10,345)
Balance (in shares) at Sep. 30, 2018	4,253,100
Balance at Sep. 30, 2018	$ 38	85,625	(82,719)	2,944
Balance (in shares) at Mar. 31, 2018	4,249,027
Balance at Mar. 31, 2018	$ 38	84,157	(75,988)	8,207
Restricted stock units vested and issued (in shares)	4,073
Restricted stock units vested and issued
Share-based compensation		738		738
Net loss			(3,217)	(3,217)
Adjustments to opening balance for change in accounting principle			30	30
Balance (in shares) at Jun. 30, 2018	4,253,100
Balance at Jun. 30, 2018	$ 38	84,895	(79,175)	5,758
Restricted stock units vested and issued
Share-based compensation		730		730
Net loss			(3,544)	(3,544)
Balance (in shares) at Sep. 30, 2018	4,253,100
Balance at Sep. 30, 2018	$ 38	85,625	(82,719)	2,944
Balance (in shares) at Dec. 31, 2018	4,845,697
Balance at Dec. 31, 2018	$ 43	90,110	(86,361)	3,792
Restricted stock units vested and issued (in shares)	2,268
Restricted stock units vested and issued	$ 1			1
Share-based compensation		690		690
Net loss			(3,665)	(3,665)
Balance (in shares) at Mar. 31, 2019	4,847,965
Balance at Mar. 31, 2019	$ 44	90,800	(90,026)	818
Balance (in shares) at Dec. 31, 2018	4,845,697
Balance at Dec. 31, 2018	$ 43	90,110	(86,361)	3,792
Net loss				$ (11,208)
Exercise of stock options (in shares)
Balance (in shares) at Sep. 30, 2019	6,825,183
Balance at Sep. 30, 2019	$ 46	102,716	(97,568)	$ 5,194
Balance (in shares) at Mar. 31, 2019	4,847,965
Balance at Mar. 31, 2019	$ 44	90,800	(90,026)	818
Share-based compensation		696		696
Net loss			(3,750)	(3,750)
Reverse stock split fractional share true up (in shares)	(494)
Balance (in shares) at Jun. 30, 2019	4,847,471
Balance at Jun. 30, 2019	$ 44	91,496	(93,776)	(2,236)
Restricted stock units vested and issued (in shares)	25,158
Restricted stock units vested and issued
Share-based compensation		756		756
Net loss			(3,792)	(3,792)
Issuance of stock and warrants, net of issuance costs (in shares)	1,741,667
Issuance of stock and warrants, net of issuance costs	$ 2	9,258		9,260
Issuance of stock and warrants from conversion of convertible notes (in shares)	210,887
Issuance of stock and warrants from conversion of convertible notes		1,206		1,206
Balance (in shares) at Sep. 30, 2019	6,825,183
Balance at Sep. 30, 2019	$ 46	$ 102,716	$ (97,568)	$ 5,194

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Operating activities:
Net loss	$ (11,208,000)	$ (10,345,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Write-off of inventory	54,000
Depreciation	78,000	66,000
Amortization of right-of-use asset	325,000
Share-based compensation	2,142,000	2,083,000
Amortization of debt discount on convertible shareholder notes	112,000
Change in fair value of redemption feature embedded in convertible notes	(52,000)
Loss on extinguishment of convertible notes	521,000
Changes in operating assets and liabilities:
Accounts receivable	171,000	(75,000)
Inventory	43,000	57,000
Prepaid expenses and other current assets	265,000	116,000
Accounts payable	372,000	200,000
Accrued expenses and other current liabilities	687,000	141,000
Deferred revenue	691,000	(65,000)
Deferred rent		(1,000)
Operating lease liability - noncurrent	(390,000)
Net cash used in operating activities	(6,189,000)	(7,823,000)
Investing activities:
Purchase of property and equipment	(144,000)	(51,000)
Net cash used in investing activities	(144,000)	(51,000)
Financing activities:
Proceeds from sale of stock and warrants, net of issuance costs	9,260,000
Proceeds from issuance of convertible loan payable	625,000
Proceeds from the exercise of common stock options		5,000
Net cash provided by financing activities	9,885,000	5,000
Net change in cash and cash equivalents	3,552,000	(7,869,000)
Cash and cash equivalents at beginning of period	5,358,000	12,689,000
Cash and cash equivalents at end of period	8,910,000	4,820,000
Supplemental disclosure for noncash investing and financing activities:
Conversion of interest payable to stock and warrants	$ 8,000

Note 1 - Summary of Business an

Note 1 - Summary of Business and Basis of Presentation	9 Months Ended
Note 1 - Summary of Business and Basis of Presentation	Sep. 30, 2019
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	( 1 Summary of Business and Basis of Presentation (a) Description of Business BioCardia, Inc., (BioCardia or the Company), is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The Company’s lead therapeutic candidate is the CardiAMP® cell therapy system and its second BioCardia also has three 1 2 ™ 3 ™

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	9 Months Ended
Note 2 - Significant Accounting Policies	Sep. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	( 2 Significant Accounting Policies (a) Basis of Preparation The accompanying condensed consolidated balance sheets, statements of operations, shareholders equity, and cash flows as of September 30, 2019 three nine September 30, 2019 2018 September 30, 2019, three nine September 30, 2019 2018, nine September 30, 2019 2018. nine September 30, 2019 not December 31, 2019 December 31, 2018 $277,000. no These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company’s Annual Report on Form 10 December 31, 2018, April 2, 2019. (b) Liquidity The Company has incurred net losses and negative cash flows from operations since its inception and had an accumulated deficit of $97.6 September 30, 2019. one $8,910,000 September 30, 2019, not one not If adequate funds are not may may no (c) Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, allowances for doubtful accounts and sales returns, incremental borrowing rate, and inventory valuation. (d) Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated during the consolidation process. (e) Changes to Significant Accounting Policies The Company’s significant accounting policies are described in Note 2 10 December 31, 2018. No. 2018 07, 718 January 1, 2019, No. 2016 02, 842 no Measurement of nonemployee awards may 505 50 Operating lease right-of-use asset and liabilities 12 The Company’s lease liabilities are recognized at the applicable lease commencement date based on the present value of the lease payments required to be paid over the lease term. Variable lease payments are expensed as incurred and are not The Company's ROU assets are also recognized at the applicable lease commencement date. The ROU asset equals the carrying amount of the related lease liability, adjusted for any lease payments made prior to lease commencement and lease incentives provided by the lessor, if any. The Company amortizes a right-of-use (ROU) asset, and the periodic amortization is the difference between the straight-line total lease cost for the period (including amortization of initial direct costs) and the periodic accretion of the lease liability using the effective interest method. The Company’s lease terms may The Company’s lease contracts often include lease and non-lease components. The Company has elected the practical expedient offered by the standard to not The Company has elected not twelve (f) Recently Adopted Accounting Pronouncement In February 2016, July 2018, No. 2018 11, 842 No. 2018 11. No. 2018 11, 2016 02, The Company adopted the new standard using the cumulative-effect method on January 1, 2019. March 2019. The FASB made available several practical expedients in adopting the amended lease accounting guidance. The Company elected the package of practical expedients permitted under the transition guidance, which among other things, allowed registrants to carry forward historical lease classification, its assessment on whether a contract is or contains a lease, and its initial direct costs for any leases that exist prior to adoption of the new standard. BioCardia also elected to keep leases with an initial term of 12 The most significant impact was the recognition of ROU assets and related lease liabilities for operating leases on the condensed consolidated balance sheet. The Company recognized ROU assets and related lease liabilities of $1,505,000 $1,593,000 January 1, 2019. not 6 In June 2018, No. 2018 07, 718 2018 07 2018 07 718, No 2018 07 505 50, 2018 07 January 1, 2019 not not (g) Recently Issued Accounting Pronouncements Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force did not not

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurement	9 Months Ended
Note 3 - Fair Value Measurement	Sep. 30, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	( 3 The fair value of financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The Company follows a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into the following three Level 1 Level 2 not Level 3 no The following table sets forth the fair value of its financial assets measured on a recurring basis as of September 30, 2019 December 31, 2018 As of September 30, 2019 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 8,910 $ — $ — $ 8,910 As of December 31, 2018 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 5,358 $ — $ — $ 5,358

Note 4 - Inventories

Note 4 - Inventories	9 Months Ended
Note 4 - Inventories	Sep. 30, 2019
Notes to Financial Statements
Inventory Disclosure [Text Block]	( 4 Inventories are stated at the lower of cost or net realizable value using the average cost method. Inventories consisted of the following (in thousands): September 30, December 31, 2019 2018 Raw materials $ — $ 79 Work in process 45 39 Finished goods — 23 Total $ 45 $ 141 Write downs for excess or expired inventory are based on management’s estimates of forecasted usage of inventories and are included in cost of goods sold. A significant change in the timing or level of demand for certain products as compared to forecasted amounts may $0, $80,000 three nine September 30, 2019, $13,000, $15,000 three nine September 30, 2018,

Note 5 - Property and Equipment

Note 5 - Property and Equipment, Net	9 Months Ended
Note 5 - Property and Equipment, Net	Sep. 30, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	( 5 Property and equipment, net consisted of the following (in thousands): September 30, December 31, 2019 2018 Computer equipment and software $ 127 119 Laboratory and manufacturing equipment 550 481 Furniture and fixtures 55 55 Leasehold improvements 332 332 Construction in progress 69 3 Property and equipment, gross 1,133 990 Less accumulated depreciation (923 ) (845 ) Property and equipment, net $ 210 145 Depreciation expense totaled approximately $29,000 $78,000 three nine September 30, 2019, $22,000 $66,000 three nine September 30, 2018,

Note 6 - Operating Lease Right-

Note 6 - Operating Lease Right-of-use Asset, Net	9 Months Ended
Note 6 - Operating Lease Right-of-use Asset, Net	Sep. 30, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	( 6 The Company adopted the new lease standard on January 1, 2019 not The Company determines if an arrangement is a lease at inception by assessing whether it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company’s operating lease is primarily related to a property lease for its laboratory and corporate offices. BioCardia’s lease agreement does not ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company’s lease does not not no not The components of lease expense for the three nine September 30, 2019 Three months ended September 30, Nine months ended September 30, 2019 2019 Straight-line rent expense recognized for operating lease $ 150 $ 450 Variable rent expense recognized for operating lease 63 202 Total rent expense $ 213 $ 652 Weighted average remaining lease term (in years) 2.25 Weighted average discount rate 12.05 % Supplemental cash flow information related to the operating lease was as follows (in thousands): Three months ended September 30, Nine months ended September 30, 2019 2019 Cash paid for amounts included in the measurement of lease liabilities $ 153 $ 459 Cash Lease Expense (imputed interest expense component of net income) 39 126 Future minimum lease payments under the operating lease as of September 30, 2019 Operating Lease September 30, 2019 Remainder of 2019 $ 153 Years ending December 31, 2020 630 2021 649 Total undiscounted lease payments 1,432 Less imputed interest 172 Total operating lease liabilities $ 1,260 Prior to the Company’s adoption of the new lease standard, future minimum lease payments as of December 31, 2018, Years ending December 31, 2019 $ 612 2020 630 2021 649 Total $ 1,891

Note 7 - Accrued Expenses and O

Note 7 - Accrued Expenses and Other Current Liabilities	9 Months Ended
Note 7 - Accrued Expenses and Other Current Liabilities	Sep. 30, 2019
Notes to Financial Statements
Accrued Liabilities and Other Current Liabilities Disclosure [Text Block]	( 7 Accrued expenses and other current liabilities consisted of the following (in thousands): September 30, December 31, 2019 2018 Accrued expenses $ 102 $ 127 Accrued salaries and employee benefits 496 368 Accrued director compensation 555 277 Accrued clinical trial costs 382 276 Grant liability 637 645 Customer deposits 252 112 Total $ 2,424 $ 1,805

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	9 Months Ended
Note 8 - Stockholders' Equity	Sep. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	( 8 Stockholders’ Equity Public Offering on Form S- 1 April 2019, 1 1 August 2, 2019, 1, 1,666,667 one $0.001 one $6.00 $6.30 five 11,958 $6.60 45 250,000 250,000 August 6, 2019. $8.84 September 4, 2019, 75,000 250,000 $420,000, $32,000. Up List to Nasdaq August 2, 2019 Convertible Note Financing July 5, 2019, $625,000 14.0% six January 5, 2020. 50% $52,000. $521,000. three nine September 31, 2019, $112,000 $104,000 Upon the closing of the Company’s public offering of units on August 6, 2019 $633,000, 210,887 one one $3.00 one $8.00 Reverse Stock Split June 6, 2019 1 9 Warrants for Common Stock December 24, 2018, 296,296 592,592 $6.75 $3.8 $200,000 six $6.75 December 24, 2023. Number of Common Stock Warrants Weighted Average Exercise Price Balance, December 31, 2018 296,296 $ 6.75 Warrants for common stock sold 2,139,512 $ 6.30 Warrants for common stock exercised - Balance, September 30,2018 2,435,808 $ 6.36

Note 9 - Share-based Compensati

Note 9 - Share-based Compensation	9 Months Ended
Note 9 - Share-based Compensation	Sep. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	( 9 ) Share-Based Compensation The share-based compensation expense is recorded in cost of goods sold, research and development, and selling, general and administrative expenses based on the employee's or non-employee’s respective function. No three nine September 30, 2019 2018 Three months ended September 30, Nine months ended September 30, 2019 2018 2019 2018 Cost of goods sold $ 38 $ 39 $ 130 $ 105 Research and development 293 250 787 711 Selling, general and administrative 425 441 1,224 1,267 Share-based compensation expense $ 756 $ 730 $ 2,142 $ 2,083 The following table summarizes the activity of stock options and related information: Options outstanding Number of shares Weighted average exercise price Balance, December 31, 2018 608,485 $ 25.16 Stock options granted 254,785 5.28 Stock options exercised — - Stock options canceled (15,122 ) 14.16 Balance, September 30, 2019 848,148 $ 18.90 Exercisable and vested, September 30, 2019 390,199 $ 24.17 Unrecognized share-based compensation for employee and nonemployee options granted through September 30, 2019 $4.0 2.3 Share-Based Compensation (RSUs) The following summarizes the activity of non-vested RSUs: Weighted average grant date Number of fair value S hares per share Balance, December 31, 2018 29,694 $ 25.56 RSUs granted 34,713 $ 4.75 RSUs vested (2,272 ) $ 99.36 RSUs forfeited - - Balance, September 30, 2019 62,135 $ 10.55 Unrecognized share-based compensation for RSUs granted through September 30, 2019 $230,000 0.3

Note 10 - Net Loss Per Share

Note 10 - Net Loss Per Share	9 Months Ended
Note 10 - Net Loss Per Share	Sep. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	( 10 Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no The following outstanding common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: September 30, 2019 2018 Stock options to purchase common stock 848,148 616,567 Unvested restricted stock units 62,135 29,706 Common stock warrants 2,435,808 - Total 3,346,091 646,273

Note 11 - Income Taxes

Note 11 - Income Taxes	9 Months Ended
Note 11 - Income Taxes	Sep. 30, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	( 11 During the three nine September 30, 2019 2018, no As of September 30, 2019, not not

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	9 Months Ended
Note 12 - Related Party Transactions	Sep. 30, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	( 12 ) Related Party Transactions BioCardia, Inc. (the “Company”) and OPKO Health, Inc. (“OPKO”) previously entered into a consulting agreement dated August 19, 2016, 5% Pursuant to the terms of the Consulting Agreement, OPKO was to provide advisory services to the Company in support of strategic transactions, financings and other matters as agreed between the parties from time to time. Also, in August 2016, ten 46,553 4 $16.20 4 one Effective August 29, 2019, no ten August 2019. $116,000 $160,000 three nine September 30, 2019, $59,000 $121,000 three nine September 30, 2018,

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	(a) Basis of Preparation The accompanying condensed consolidated balance sheets, statements of operations, shareholders equity, and cash flows as of September 30, 2019 three nine September 30, 2019 2018 September 30, 2019, three nine September 30, 2019 2018, nine September 30, 2019 2018. nine September 30, 2019 not December 31, 2019 December 31, 2018 $277,000. no These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company’s Annual Report on Form 10 December 31, 2018, April 2, 2019.
Going Concern and Liquidity [Policy Text Block]	(b) Liquidity The Company has incurred net losses and negative cash flows from operations since its inception and had an accumulated deficit of $97.6 September 30, 2019. one $8,910,000 September 30, 2019, not one not If adequate funds are not may may no
Use of Estimates, Policy [Policy Text Block]	(c) Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, allowances for doubtful accounts and sales returns, incremental borrowing rate, and inventory valuation.
Consolidation, Policy [Policy Text Block]	(d) Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated during the consolidation process.
Change to Significant Accounting Policies [Policy Text Block]	(e) Changes to Significant Accounting Policies The Company’s significant accounting policies are described in Note 2 10 December 31, 2018. No. 2018 07, 718 January 1, 2019, No. 2016 02, 842 no Measurement of nonemployee awards may 505 50 Operating lease right-of-use asset and liabilities 12 The Company’s lease liabilities are recognized at the applicable lease commencement date based on the present value of the lease payments required to be paid over the lease term. Variable lease payments are expensed as incurred and are not The Company's ROU assets are also recognized at the applicable lease commencement date. The ROU asset equals the carrying amount of the related lease liability, adjusted for any lease payments made prior to lease commencement and lease incentives provided by the lessor, if any. The Company amortizes a right-of-use (ROU) asset, and the periodic amortization is the difference between the straight-line total lease cost for the period (including amortization of initial direct costs) and the periodic accretion of the lease liability using the effective interest method. The Company’s lease terms may The Company’s lease contracts often include lease and non-lease components. The Company has elected the practical expedient offered by the standard to not The Company has elected not twelve
New Accounting Pronouncements, Policy [Policy Text Block]	(f) Recently Adopted Accounting Pronouncement In February 2016, July 2018, No. 2018 11, 842 No. 2018 11. No. 2018 11, 2016 02, The Company adopted the new standard using the cumulative-effect method on January 1, 2019. March 2019. The FASB made available several practical expedients in adopting the amended lease accounting guidance. The Company elected the package of practical expedients permitted under the transition guidance, which among other things, allowed registrants to carry forward historical lease classification, its assessment on whether a contract is or contains a lease, and its initial direct costs for any leases that exist prior to adoption of the new standard. BioCardia also elected to keep leases with an initial term of 12 The most significant impact was the recognition of ROU assets and related lease liabilities for operating leases on the condensed consolidated balance sheet. The Company recognized ROU assets and related lease liabilities of $1,505,000 $1,593,000 January 1, 2019. not 6 In June 2018, No. 2018 07, 718 2018 07 2018 07 718, No 2018 07 505 50, 2018 07 January 1, 2019 not not (g) Recently Issued Accounting Pronouncements Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force did not not

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurement (Tables)	9 Months Ended
Note 3 - Fair Value Measurement (Tables)	Sep. 30, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	As of September 30, 2019 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 8,910 $ — $ — $ 8,910 As of December 31, 2018 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 5,358 $ — $ — $ 5,358

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)	9 Months Ended
Note 4 - Inventories (Tables)	Sep. 30, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, December 31, 2019 2018 Raw materials $ — $ 79 Work in process 45 39 Finished goods — 23 Total $ 45 $ 141

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment, Net (Tables)	9 Months Ended
Note 5 - Property and Equipment, Net (Tables)	Sep. 30, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, December 31, 2019 2018 Computer equipment and software $ 127 119 Laboratory and manufacturing equipment 550 481 Furniture and fixtures 55 55 Leasehold improvements 332 332 Construction in progress 69 3 Property and equipment, gross 1,133 990 Less accumulated depreciation (923 ) (845 ) Property and equipment, net $ 210 145

Note 6 - Operating Lease Righ_2

Note 6 - Operating Lease Right-of-use Asset, Net (Tables)	9 Months Ended
Note 6 - Operating Lease Right-of-use Asset, Net (Tables)	Sep. 30, 2019
Notes Tables
Lease, Cost [Table Text Block]	Three months ended September 30, Nine months ended September 30, 2019 2019 Straight-line rent expense recognized for operating lease $ 150 $ 450 Variable rent expense recognized for operating lease 63 202 Total rent expense $ 213 $ 652 Weighted average remaining lease term (in years) 2.25 Weighted average discount rate 12.05 %
Schedule of Operating Leases Cash Flow Information [Table Text Block]	Three months ended September 30, Nine months ended September 30, 2019 2019 Cash paid for amounts included in the measurement of lease liabilities $ 153 $ 459 Cash Lease Expense (imputed interest expense component of net income) 39 126
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Operating Lease September 30, 2019 Remainder of 2019 $ 153 Years ending December 31, 2020 630 2021 649 Total undiscounted lease payments 1,432 Less imputed interest 172 Total operating lease liabilities $ 1,260
Lessee, Operating Lease, Disclosure [Table Text Block]	Years ending December 31, 2019 $ 612 2020 630 2021 649 Total $ 1,891

Note 7 - Accrued Expenses and_2

Note 7 - Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block]	<table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">September 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">102</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">127</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued salaries and employee benefits</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">496</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">368</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued director compensation</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">555</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">277</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued clinical trial costs</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">382</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">276</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Grant liability</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">637</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">645</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer deposits</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">252</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">112</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,424</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,805</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>" id="sjs-B4"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">September 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">102</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">127</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued salaries and employee benefits</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">496</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">368</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued director compensation</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">555</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">277</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued clinical trial costs</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">382</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">276</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Grant liability</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">637</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">645</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer deposits</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">252</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">112</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,424</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,805</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Tables)	9 Months Ended
Note 8 - Stockholders' Equity (Tables)	Sep. 30, 2019
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Common Stock Warrants Weighted Average Exercise Price Balance, December 31, 2018 296,296 $ 6.75 Warrants for common stock sold 2,139,512 $ 6.30 Warrants for common stock exercised - Balance, September 30,2018 2,435,808 $ 6.36

Note 9 - Share-based Compensa_2

Note 9 - Share-based Compensation (Tables)	9 Months Ended
Note 9 - Share-based Compensation (Tables)	Sep. 30, 2019
Notes Tables
Schedule of Share-based Compensation, Expense [Table Text Block]	Three months ended September 30, Nine months ended September 30, 2019 2018 2019 2018 Cost of goods sold $ 38 $ 39 $ 130 $ 105 Research and development 293 250 787 711 Selling, general and administrative 425 441 1,224 1,267 Share-based compensation expense $ 756 $ 730 $ 2,142 $ 2,083
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Options outstanding Number of shares Weighted average exercise price Balance, December 31, 2018 608,485 $ 25.16 Stock options granted 254,785 5.28 Stock options exercised — - Stock options canceled (15,122 ) 14.16 Balance, September 30, 2019 848,148 $ 18.90 Exercisable and vested, September 30, 2019 390,199 $ 24.17
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Weighted average grant date Number of fair value S hares per share Balance, December 31, 2018 29,694 $ 25.56 RSUs granted 34,713 $ 4.75 RSUs vested (2,272 ) $ 99.36 RSUs forfeited - - Balance, September 30, 2019 62,135 $ 10.55

Note 10 - Net Loss Per Share (T

Note 10 - Net Loss Per Share (Tables)	9 Months Ended
Note 10 - Net Loss Per Share (Tables)	Sep. 30, 2019
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	September 30, 2019 2018 Stock options to purchase common stock 848,148 616,567 Unvested restricted stock units 62,135 29,706 Common stock warrants 2,435,808 - Total 3,346,091 646,273

Note 2 - Significant Accounti_2

Note 2 - Significant Accounting Policies (Details Textual) - USD ($)	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Accounts Payable, Current, Total	$ 1,112,000		$ 743,000
Retained Earnings (Accumulated Deficit), Ending Balance	(97,568,000)		(86,361,000)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	8,910,000		5,358,000	$ 4,820,000	$ 12,689,000
Operating Lease, Right-of-Use Asset	1,180,000	$ 1,505,000
Operating Lease, Liability, Total	1,260,000	$ 1,593,000
Accrued Liabilities and Other Liabilities, Current	$ 2,424,000		1,805,000
Restatement Adjustment [Member]
Accounts Payable, Current, Total			(277,000)
Accrued Liabilities and Other Liabilities, Current			$ 277,000

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Money market funds	$ 8,910	$ 5,358
Fair Value, Inputs, Level 1 [Member]
Money market funds	8,910	5,358
Fair Value, Inputs, Level 2 [Member]
Money market funds
Fair Value, Inputs, Level 3 [Member]
Money market funds

Note 4 - Inventories (Details T

Note 4 - Inventories (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
Note 4 - Inventories (Details Textual) - USD ($)	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Inventory Write-down			$ 54,000
Cost of Goods Sold [Member]
Inventory Write-down	$ 0	$ 13,000	$ 80,000	$ 15,000

Note 4 - Inventories - Summary

Note 4 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Raw materials		$ 79
Work in process	45	39
Finished goods		23
Total	$ 45	$ 141

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment, Net (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Depreciation, Total	$ 29,000	$ 22,000	$ 78,000	$ 66,000

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Property and equipment, gross	$ 1,133	$ 990
Less accumulated depreciation	(923)	(845)
Property and equipment, net	210	145
Computer Equipment and Software [Member]
Property and equipment, gross	127	119
Laboratory and Manufacturing Equipment [Member]
Property and equipment, gross	550	481
Furniture and Fixtures [Member]
Property and equipment, gross	55	55
Leasehold Improvements [Member]
Property and equipment, gross	332	332
Construction in Progress [Member]
Property and equipment, gross	$ 69	$ 3

Note 6 - Operating Lease Righ_3

Note 6 - Operating Lease Right-of-use Asset, Net - Impact of New Lease Standard (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2019USD ($)
Straight-line rent expense recognized for operating lease	$ 150	$ 450
Variable rent expense recognized for operating lease	63	202
Total rent expense	$ 213	$ 652
Weighted average remaining lease term (in years) (Year)	2 years 91 days	2 years 91 days
Weighted average discount rate	12.05%	12.05%

Note 6 - Operating Lease Righ_4

Note 6 - Operating Lease Right-of-use Asset, Net - Supplement Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Cash paid for amounts included in the measurement of lease liabilities	$ 153	$ 459
Cash Lease Expense (imputed interest expense component of net income)	$ 39	$ 126

Note 6 - Operating Lease Righ_5

Note 6 - Operating Lease Right-of-use Asset, Net - Future Minimum Lease Payments Under Operating Lease (Details) - USD ($)	Sep. 30, 2019	Jan. 01, 2019
Remainder of 2019	$ 153,000
2020	630,000
2021	649,000
Total undiscounted lease payments	1,432,000
Less imputed interest	172,000
Total operating lease liabilities	$ 1,260,000	$ 1,593,000

Note 6 - Operating Lease Righ_6

Note 6 - Operating Lease Right-of-use Asset, Net - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2018USD ($)
2019	$ 612
2020	630
2021	649
Total	$ 1,891

Note 7 - Accrued Expenses and_3

Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accrued expenses	$ 102	$ 127
Accrued salaries and employee benefits	496	368
Accrued director compensation	555	277
Accrued clinical trial costs	382	276
Grant liability	637	645
Customer deposits	252	112
Total	$ 2,424	$ 1,805

Note 8 - Stockholders' Equity_2

Note 8 - Stockholders' Equity (Details Textual)	Sep. 04, 2019USD ($)shares	Aug. 06, 2019USD ($)$ / sharesshares	Aug. 06, 2019USD ($)$ / sharesshares	Aug. 02, 2019$ / sharesshares	Jul. 05, 2019USD ($)shares	Jun. 06, 2019	Dec. 24, 2018USD ($)$ / sharesshares	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)	Aug. 05, 2019$ / shares	Dec. 31, 2018$ / sharesshares
Common Stock, Par or Stated Value Per Share \| $ / shares								$ 0.001	$ 0.001			$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares							$ 6.75	$ 6.36	$ 6.36			$ 6.75
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							296,296
Class of Warrant or Right, Issued During Period									2,139,512
Common Stock, Shares, Issued, Total							592,592	6,825,183	6,825,183			4,845,697
Sale of Stock, Price Per Share \| $ / shares							$ 6.75
Proceeds from Issuance of Common Stock and Warrants \| $							$ 3,800,000		$ 9,260,000
Payments of Stock Issuance Costs \| $							$ 200,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio						9
Conversion of Convertible Notes to Units [Member]
Debt Conversion, Original Debt, Amount \| $			$ 633,000		$ 52,000
Debt Conversion, Converted Instrument, Shares Issued			210,887		521,000
Interest Expense, Debt, Total \| $								$ 112,000
Amortization of Debt Discount (Premium) \| $								$ 104,000
Convertible Promissory Note [Member]
Proceeds from Convertible Debt \| $					$ 625,000
Debt Instrument, Interest Rate, Stated Percentage					14.00%
Debt Conversion, Original Debt, Discount of Securities Offered					50.00%
Underwriters [Member]
Proceeds from Issuance or Sale of Equity, Total \| $	$ 420,000
Stock Issued During Period, Shares, New Issues	75,000
Class of Warrant or Right, Issued During Period	250,000
Underwriting Discounts and Commissions \| $	$ 32,000
Warrants Issued to Underwriters [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 6.60
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				11,958
Public Offering [Member]
Number of Units Offered to Sale				1,666,667
Number of Common Stock in Each Unit				1
Common Stock, Par or Stated Value Per Share \| $ / shares				$ 0.001
Number of Common Stock Called by Each Unit				1
Unit Offering Price \| $ / shares				$ 6
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 6.30
Warrants and Rights Outstanding, Term				5 years
Underwriters, Additional Common Shares Authorized to Purchase				250,000
Underwriters, Additional Warrants Authorized to Purchase				250,000
Proceeds from Issuance or Sale of Equity, Total \| $		$ 8,840,000
Number of Warrants in Each Unit				1
Private Placement Unit [Member]
Number of Common Stock in Each Unit		1	1
Number of Common Stock Called by Each Unit		1	1
Debt Instrument, Convertible, Conversion Price \| $ / shares		$ 3	$ 3								$ 8
Number of Warrants in Each Unit		1	1

Note 8 - Stockholders' Equity -

Note 8 - Stockholders' Equity - Warrants (Details)	9 Months Ended
Note 8 - Stockholders' Equity - Warrants (Details)	Sep. 30, 2019$ / sharesshares
Balance, December 31, 2018 (in shares) \| shares	296,296
Balance, December 31, 2018 (in dollars per share) \| $ / shares	$ 6.75
Warrants for common stock sold (in shares) \| shares	2,139,512
Warrants for common stock sold (in dollars per share) \| $ / shares	$ 6.30
Balance, September 30,2018 (in shares) \| shares	2,435,808
Balance, September 30,2018 (in dollars per share) \| $ / shares	$ 6.36

Note 9 - Share-based Compensa_3

Note 9 - Share-based Compensation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Payment Arrangement, Amount Capitalized	$ 0	$ 0	$ 0	$ 0
Non-employee Directors and Employees [Member]
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	4,000,000		$ 4,000,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			2 years 109 days
Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	$ 230,000		$ 230,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			109 days

Note 9 - Share-based Compensa_4

Note 9 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based compensation expense	$ 756	$ 730	$ 2,142	$ 2,083
Cost of Goods Sold [Member]
Share-based compensation expense	38	39	130	105
Research and Development Expense [Member]
Share-based compensation expense	293	250	787	711
Selling, General and Administrative Expenses [Member]
Share-based compensation expense	$ 425	$ 441	$ 1,224	$ 1,267

Note 9 - Share-based Compensa_5

Note 9 - Share-based Compensation - Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Stock options outstanding, beginning of period (in shares) \| shares	608,485
Balance, weighted average exercise price, beginning of period (in dollars per share) \| $ / shares	$ 25.16
Stock options granted (in shares) \| shares	254,785
Stock options granted, weighted average exercise price (in dollars per share) \| $ / shares	$ 5.28
Stock options exercised (in shares) \| shares
Stock options exercised, weighted average exercise price (in dollars per share) \| $ / shares
Stock options canceled (in shares) \| shares	(15,122)
Stock options canceled, weighted average exercise price (in dollars per share) \| $ / shares	$ 14.16
Balance, September 30, 2019 (in shares) \| shares	848,148
Balance, September 30, 2019 (in dollars per share) \| $ / shares	$ 18.90
Exercisable and vested (in shares) \| shares	390,199
Exercisable and vested, weighted average exercise price (in dollars per share) \| $ / shares	$ 24.17

Note 9 - Share-based Compensa_6

Note 9 - Share-based Compensation - Summary of Non-vested RSUs (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Balance, December 31, 2018 (in shares) \| shares	29,694
Balance, December 31, 2018 (in dollars per share) \| $ / shares	$ 25.56
RSUs granted, shares (in shares) \| shares	34,713
RSUs granted, weighted average grant date fair value per share (in dollars per share) \| $ / shares	$ 4.75
RSUs vested, shares (in shares) \| shares	(2,272)
RSUs vested, weighted average grant date fair value per share (in dollars per share) \| $ / shares	$ 99.36
RSUs forfeited, shares (in shares) \| shares
RSUs forfeited, weighted average grant date fair value per share (in dollars per share) \| $ / shares
Balance, September 30, 2019 (in shares) \| shares	62,135
Balance, September 30, 2019 (in dollars per share) \| $ / shares	$ 10.55

Note 10 - Net Loss Per Share -

Note 10 - Net Loss Per Share - Anti-dilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Antidilutive securities (in shares)	3,346,091	646,273
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	848,148	616,567
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)	62,135	29,706
Warrant [Member]
Antidilutive securities (in shares)	2,435,808

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Tax Expense (Benefit), Total	$ 0	$ 0	$ 0	$ 0
Deferred Tax Liabilities, Net, Total	$ 0		$ 0

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 31, 2016	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Aug. 19, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				254,785
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance		$ 18.90		$ 18.90		$ 25.16
Share-based Payment Arrangement, Noncash Expense, Total				$ 2,142,000	$ 2,083,000
Chairman and Chief Executive Officer of OPKO [Member]
Related Party, Ownership Percentage							5.00%
Chairman and Chief Executive Officer of OPKO [Member] \| OPKO [Member]
Share-based Payment Arrangement, Noncash Expense, Total		$ 116,000	$ 59,000	$ 160,000	$ 121,000
OPKO [Member] \| Consulting Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	46,553
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance	$ 16.20
Consulting Agreement, Term	4 years
Consulting Agreement, Term, Length of Automatic Renewal Periods	1 year